Clinical Trial of Anti-Oxidant Astaxanthin in Insulin-Resistant Subjects
Study Description
“Clinical Trial of Anti-oxidant Astaxanthin in Insulin-resistant Subjects”
Astaxanthin is a natural compound, present in many foodstuffs and available as a nutritional supplement that has been shown to have beneficial effects on many of the features of insulin resistance/glucose intolerance, at least in animals. The goal of this project is to provide a validation of astaxanthin effects on metabolic regulation in humans and their mechanism(s) of action, to determine if astaxanthin could have any value as a "neutraceutical" to help improve regulation of glucose and fat metabolism in subjects with insulin resistance/ glucose intolerance.
Location
Methods
No pharmaceutical medication involved
Patients and healthy individuals accepted
Dietary Supplement - Astaxanthin
The agent to be tested is astaxanthin, isolated from H. pluvialis following GMP standards. A GRAS notice (GRN000294) was accepted by the Food and Drug Administration (FDA) in January 2010. Agent is stored in capsules at room temperature.
Placebo
Matching placebo pill
Additional Information
Official Study Title
A Double-blinded, Placebo-controlled, Clinical Trial of Insulin-sensitizing, Anti-inflammatory and Anti-oxidant Activities of Astaxanthin in Insulin-resistant Subjects
Clinical Trial ID
NCT03310359
ParticipAid ID
nel1la
